Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
We are very encouraged by the results of the LC-FAOD Phase1b study, said Dr. Alejandro Dorenbaum, Chief Medical Officer of Reneo Pharmaceuticals, Inc. Safety and tolerability of REN001 in this study was consistent with prior REN001 studies.
- We are very encouraged by the results of the LC-FAOD Phase1b study, said Dr. Alejandro Dorenbaum, Chief Medical Officer of Reneo Pharmaceuticals, Inc. Safety and tolerability of REN001 in this study was consistent with prior REN001 studies.
- The Company intends to present additional data from the LC-FAOD studies at a medical conference in 2022.
- Over two-thirds of the patients have been enrolled into the 24-week study, with enrollment on track to be completed by year-end 2022.
- REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.